Mosunetuzumab▽ Plus Polatuzumab Vedotin has Promising Efficacy and a Favorable Safety Profile in Patients with Relapsed/Refrac
FDA Approves Bispecific Antibody Mosunetuzumab for R/R Follicular Lymphoma
Raul Cordoba, MD, PhD on Twitter: "#ASH19 Mosunetuzumab induces CR in poor prognosis NHL patients including those who are resistant to or relapsing after #CART therapies #lymsm. Data coming from the first
Mosunetuzumab shows deep, durable responses in advanced follicular lymphoma
Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapse
EU approves Roche's Lunsumio to treat relapsed or refractory follicular lymphoma | Companies | POST Online Media
Industry News_Shanghai Jiaoze Industrial Co., Ltd.
Antibodies | Free Full-Text | The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
ASH 2022: Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study
Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study -
Roche eyes year-end Lunsumio FDA bispecific verdict in lymphoma
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study - The Lancet Oncology
Roche presents new data from its bispecific antibody
Roche challenges CAR-T with bispecific blood cancer approval
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With
European Commission approves Roche's first-in-class
SOHO 2022: Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase
Pharma News | Gilead, Roche, AstraZeneca, Genentech, Mirati, Pfizer
FDA Approves Lunsumio (mosunetuzumab-axgb) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Roche presents latest advances with immunotherapies in non-Hodgkin lym
Mosunetuzumab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts | Fierce Biotech
Ash 2019 – Roche doesn't disappoint with bispecific | Evaluate
